Zydus receives final approval for Temozolomide Capsules

Capital Market 

From USFDA

Zydus Cadila has received final approval from USFDA to market Temozolomide Capsules in strengths of 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg. Temozolomide capsule is a chemotheraphy drug used in the management of brain tumors.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)